• Home
  • CBD News
  • CBD Uses
  • CBD Products
  • Contact Us
No Result
View All Result
Cbdnewshubb
Advertisement Banner
  • Home
  • CBD News
  • CBD Uses
  • CBD Products
  • Contact Us
No Result
View All Result
Cbdnewshubb
No Result
View All Result
Home CBD Uses

FDA approves new study: Ketamine For Depressive Disorder

admin by admin
December 19, 2022
in CBD Uses


The U.S Food and Drug Administration (FDA) has just completed reviewing an application of an Investigational New Drug (“IND”) from Ehave Inc, a medical provider with special focus on psychedelics and mental health. Consequently, the FDA has approved Ehave’s first-of-a-kind clinical trial investigating intravenous administration of ketamine to treat major depression disorder (MDD). This is an open label study analyzing brain responses (electrographic responses) of patients suffering from major depression prior, during, and after they receive the drug  ketamine for a period of four weeks. The ketamine will be administered as an intravenous infusion in a clinical setup.

Ehave’s clinical trial will include 35 participants. These are patients with major depressive disorder who have failed to respond to at least two conventional antidepressants at a sufficient dose and duration. An electroencephalography machine will be used to measure the patients’ brain activities at baseline, during, and after the four weeks of the study period. The lead author of this study is Dr. Jeffrey Kamlet will be working together with Tristar Wellness on this trial. Dr. Kamlet has been the principal investigator in over 20 major pharmaceutical clinical studies. 

Over 260 million people globally have experienced a major depressive episode. Severe depression has linked to suicide, the second leading cause of death among the youth (15-29 years).  Patients with major depression often fail to respond to conventional treatments. 

Preliminary research has shown that ketamine may help to minimize suicidal tendencies, depressive symptoms, and mood fluctuations in severe depression. Intravenous ketamine administration may offer a breakthrough treatment for major depression disorder.



Source link

Previous Post

How to Sell Your Cannabis Beauty Brand This Holiday Season

Next Post

Is CBD Vegan-Friendly? | Fusion CBD Products

Next Post

Is CBD Vegan-Friendly? | Fusion CBD Products

Harvest Ball 2022 Photo Gallery

Cannabis for Inflammation: Study Finds THC and CBG More Effective than CBD

Popular Post

CBD for Sex– Relaxation, Libido, & Arousal

by admin
February 7, 2023

How Does E-beam Irradiation Affect Cannabis

by admin
February 7, 2023

Coast Launches Cannabis Vapes with Intergalactic Flavors That are Out of

by admin
February 6, 2023

How Long Does THC Vape Stay in System

by admin
February 6, 2023

CannaReg Summit 2023 Program to Feature Cannabis Beverage Association,

by admin
February 5, 2023

CBD Drink Water: What Is It & Its Benefits

by admin
February 5, 2023

cbd-44

© 2022 CBD News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • CBD News
  • CBD Uses
  • CBD Products
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • CBD News
  • CBD Uses
  • CBD Products
  • Contact Us

© 2022 CBD News Hubb All rights reserved.